Goldman Sachs and EQT Private Equity Buy Parexel in $8.5 Billion Deal

Goldman Sachs and EQT Private Equity (EQT IX) have purchased clinical research organization Parexel. The deal cost $8.5 billion and is the latest of a growing number of mergers and acquisitions throughout the COVID-19 pandemic.

“The Covid-19 pandemic has kicked the contract research field into high gear, with a particular focus on decentralized trials as the research tool of the future. With so much work — and cash — flying around, some deep-pocketed investors are signing big checks to get in on the game. Count Goldman Sachs among them.” Read more here.

(Source: Kyle Blankenship, Endpoints News, 7/2/21)